Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial

Overview of attention for article published in The Lancet Respiratory Medicine, April 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 7 news outlets
blogs: 3 blogs

twitter: 39 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 4 Mendeley

Summary News Blogs X Dimensions citations

So far, Altmetric has seen 41 X posts from 39 X users, with an upper bound of 132,682 followers.

Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial - The Lancet Respiratory Medicine #bpd #neotwitter https://t.co/u3eALllU95

01 Jun 2024

Reply Repost Favourite

RT @EPIQ_LHG: EPIQ LHG Article of the Month (April 2024): Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC…

30 Apr 2024

Reply Repost Favourite

EPIQ LHG Article of the Month (April 2024): Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial - The Lancet Respiratory Medicine https://t.co/2PcFRAsbBD

30 Apr 2024

Reply Repost Favourite

AZTEC trial: prophylactic Azithromycin doesn’t prevent BPD #neotwitter https://t.co/a5frlEq6Lq

30 Apr 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 37 additional X posts.